We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate

By HospiMedica International staff writers
Posted on 20 May 2020
Print article
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Vibalogics GmbH (Cuxhaven, Germany) will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies (Beerse, Belgium).

Vibalogics, a global contract development and manufacturing organization that specializes in the production of virotherapy products, is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate. Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.

“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”

“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”

Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH


New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Blanket Warming Cabinet
EC250
New
Anterior Cervical Plate System
XTEND

Print article

Channels

Critical Care

view channel
Image: The BrioVAD System featuring the innovative BrioVAD Pump (Photo courtesy of BrioHealth Solutions)

Innovative Ventricular Assist Device Provides Long-Term Support for Advanced Heart Failure Patients

Advanced heart failure represents the final stages of heart failure, where the heart’s ability to pump blood effectively is severely compromised. This condition often results from underlying health issues... Read more

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.